Intracellular signal pathways: Potential for therapies

Harris Perlman*, Melissa Mavers, Eric M. Ruderman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Drawbacks to current therapies for rheumatoid arthritis and the high cost of many of these drugs have lead to the investigation of novel approaches for treatment of this disease. One such tactic is the targeting of proteins involved in intracellular signal transduction. Inhibitors of p38 kinase have largely failed in clinical trials, due to both lack of efficacy and adverse events. The degree of adverse events may reflect off-target effects or, conversely, may be a mechanism-related event subsequent to successful inhibition of p38. Drugs targeting Janus kinases or spleen tyrosine kinase have shown greater success in clinical trials. A thorough analysis of specificity, as well as publication of both positive and negative results, must be the goal of continuing trials of these and other inhibitors of signal transduction molecules. The success of many clinical trials in this novel class of drugs provides optimism that more cost-effective and improved therapies will soon be available.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalCurrent rheumatology reports
Issue number5
StatePublished - Oct 2009

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Intracellular signal pathways: Potential for therapies'. Together they form a unique fingerprint.

Cite this